Mitchell Chan - 06 May 2026 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Reporting relationship: Director
Issuer ticker: AVTX
Reported as of: 06 May 2026
Net transaction value: -$72,461
SEC form: 4
Accepted by SEC: 07 May 2026, 16:15:10 UTC
Prior SEC filing: 31 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Christopher Sullivan, Attorney-in-Fact

Key filing fact

Mitchell Chan filed Form 4 for Avalo Therapeutics, Inc. (AVTX) on 07 May 2026.

Key facts

This page summarizes Mitchell Chan's Form 4 filing for Avalo Therapeutics, Inc. (AVTX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 07 May 2026, 16:15.

Change

Previous filing in this sequence was filed on 31 Mar 2026.
Current net transaction value: -$72,461.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001789335 Primary reporting owner

Chan Mitchell

Relationship: Director
Address: C/O AVALO THERAPEUTICS, INC., 1500 LIBERTY RIDGE DRIVE, SUITE 321, WAYNE
Signature: /s/ Christopher Sullivan, Attorney-in-Fact
Signature date: 07 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AVTX transaction

Common Stock

Sale

Transaction value: $72,461
Shares: -3,167
Change %: -50%
Price: $22.88
Shares after: 3,166
Date: 06 May 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 1 footnote

Footnote F1

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2025.